Amikacin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Amikacin and local guidelines before prescribing.
Mechanism
Aminoglycoside binding the 30S ribosome to inhibit bacterial protein synthesis.
Uses
Serious Gram-negative infections resistant to gentamicin; some mycobacterial infections.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Nephrotoxicity, ototoxicity (vestibular and cochlear), neuromuscular blockade.
Interactions
Loop diuretics, ciclosporin and other nephrotoxic agents increase toxicity; neuromuscular blockers potentiated.
Contraindications and cautions
Myasthenia gravis; caution in renal impairment, hearing loss
Monitoring
Levels, creatinine, audiology on prolonged use
Pregnancy and breastfeeding
Avoid (fetal ototoxicity)
Renal and hepatic impairment
Dose by level in renal impairment
Overdose and reversal
Haemodialysis; calcium for neuromuscular block
Special advice
Monitor levels and renal function; adjust dose for renal impairment; avoid in myasthenia gravis.
More from the textbook: uses, cautions and other points
- MAC: Rifampicin, ethambutol and azithromycin , continued for at least 12 months after cultures become negative. Amikacin (IV or nebulised) for severe or refractory disease.
Respiratory: Infections - Aminoglycosides (gentamicin, amikacin, tobramycin) | Permanent cochlear (high-frequency hearing loss) and vestibular toxicity (gentamicin — oscillopsia, imbalance); risk with high or prolonged levels, renal impairment, loop diuretics; MT-RNR1 m.1555A>G carriers can go deaf after a single dose — monitor levels, shortest course, …
ENT Anatomy Physiology - Aminoglycosides (gentamicin, amikacin, tobramycin) | Permanent hearing loss and balance loss (vestibular toxicity -"oscillopsia" and unsteadiness). Monitor levels; higher risk with the m.1555A>G mitochondrial variant (rapid genetic testing in neonatal units).
ENT: Common Ear disorders - Protein synthesis -30S ribosome | Aminoglycosides (gentamicin, amikacin), tetracyclines (doxycycline)
ID: How Infection Happens - Amikacin | As for gentamicin (different targets) | Ototoxicity, nephrotoxicity
ID: How Infection Happens - Protein synthesis 30S | Aminoglycosides | Gentamicin, amikacin, tobramycin | Gram-negative, synergy in endocarditis; nephro- and ototoxic; concentration-dependent
Microbiology: Diagnostic microbiology, antimicrobials and resistance
Where it is discussed in the book
- Respiratory: Infections (1 mention)
- ENT Anatomy Physiology (1 mention)
- ENT: Common Ear disorders (1 mention)
- ID: How Infection Happens (2 mentions)
- Integrated respiratory chapter (1 mention)
- Microbiology: Diagnostic microbiology, antimicrobials and resistance (1 mention)